CASE REPORT

A giant phyllodes tumor causing ulceration and severe breast disfigurement: case report and review of giant phyllodes

Mohammed A. Sbeih1,*, Ryan Engdahl2, Marina Landa3, Oreoluwa Ojetiku4, Norman Morrison2, and Hector Depaz5

1Department of Surgery, Division of General Surgery, Harlem Hospital Center, Columbia University, New York, NY, USA, 2Division of Plastic and Reconstructive Surgery, Harlem Hospital Center, Columbia University, New York, NY, USA, 3Department of Pathology, Harlem Hospital Center, Columbia University, New York, NY, USA, 4Department of Radiology, Harlem Hospital Center, Columbia University, New York, NY, USA, and 5Division of Breast Surgery, Harlem Hospital Center, Columbia University, New York, NY, USA

*Correspondence address. Department of Surgery, Division of General Surgery, Harlem Hospital Center, Columbia University, 506 Lenox Ave., New York, NY 10037, USA. Tel: +1-917-755-7274; E-mail: mohd.sbeih@nychhc.org

Abstract

Phyllodes tumors are rare fibroepithelial tumors that account for <1% of the breast tumors in women. These tumors are often benign unilateral lesions of the female breast (70%). Less common are malignant phyllodes, which have the potential for hematogenous spread. Phyllodes tumors can be seen in all age groups, and the median age of presentation is 45 years. Surgery is the main form of treatment. Wide excisions with margins of 1 cm are suggested. While smaller and moderate size phyllodes may typically be seen, gigantic ones are very rare. These may be seen in neglected tumors. By definition, a giant phyllodes tumor is one larger than 10 cm in diameter. We report a gigantic phyllodes tumor that grew over 7 years period causing significant ulceration and disfigurement and review features of these tumors and management.

INTRODUCTION

Phyllodes tumors are rare fibroepithelial tumors that account for <1% of the breast tumors. These tumors are often benign. A giant breast mass in females in the fourth and fifth decades of life should prompt consideration of phyllodes. Currently, biopsy is needed to diagnose phyllodes. The treatment for phyllodes tumors is wide local excision with sufficient margin of normal breast tissue or mastectomy. Mastectomy is often required in the case of giant phyllodes. Appropriate cutoff values for tumor size and associated prognosis are not well defined.

CASE REPORT

A 41-year-old Asian female presented to the outpatient breast surgery clinic in our hospital with a 7-year history of an enlarging left breast mass. Over the last 8 months, she reported discomfort as well as ulceration with occasional bleeding. The worsening symptoms prompted her to seek medical care. On further review, she stated that she had sought no help as she thought the mass might disappear spontaneously. She was otherwise healthy without prior surgery. She had no family history of breast or ovarian cancer. On physical examination, she had a large nodular...
mass measuring \( \sim 25 \times 20 \) cm involving the entire left breast with two periareolar areas of skin ulceration measuring \( \sim 2 \times 2 \) and \( 3 \times 4 \) cm (Fig. 1). There was a palpable left axillary lymph node 2 cm in diameter. Her right breast and the rest of her clinical examination were normal.

Due to pain and size of the right breast mass, the patient was unable to have mammography. Bilateral breast and axillary ultrasonography was performed. This showed a large heterogeneous solid mass with internal vascularity replacing all normal expected left breast tissue (Fig. 2). The size was difficult to be accurately defined on ultrasonography due to its large size. In the left axilla, a 1.8-cm nonspecific lymph node was identified with slightly prominent cortices. There were no suspicious findings in the right breast or right axilla. The patient had core biopsies of the left breast and left axillary node. Initial histopathological analysis suggested a fascicular pseudoangiomatous stromal hyperplasia or phyllodes tumor. The left axillary lymph node biopsy revealed chronic lymphadenitis without neoplastic cells. Further workup with a chest and abdomen computed tomography (CT) scan was performed, which showed no evidence of metastatic lesion.

A left mastectomy was performed. The excised mass was \( 20 \times 20 \times 25 \) cm in size (Fig. 3). The tumor did not appear grossly

Figure 1: The left breast mass measured \( 25 \times 20 \) cm with skin ulceration and severe disfigurement. The contralateral breast was normal.

Figure 2: Left breast ultrasound demonstrates a heterogeneous solid mass with internal vascularity replacing the normal breast tissue.

Figure 3: The excised mass, \( \sim 20 \times 20 \times 25 \) cm in size.
to be invading the chest wall. The pectoralis fascia was free of tumor invasion (Fig. 4). The left chest wall defect was covered temporarily with dual layers dermal regeneration template consists of thin outer layer of silicone and thick inner matrix layer of pure bovine collagen and glycosaminoglycan (INTEGRA®) in the same operation, and subsequently replaced with split thickness skin graft 5 weeks later (Fig. 5). Final histological examination was consistent with phyllodes tumor with low-grade malignant features with negative margins (Fig. 6).

FIGURE 4: The left chest wall defect after tumor resection.

FIGURE 5: Coverage of the left chest wall defect with a split thickness skin graft.

DISCUSSION

Phyllodes tumors are rare fibroepithelial breast tumors that have both epithelial and stromal elements. These tumors comprise <1% of primary breast tumors [1]. They typically present as mobile rounded nodules or masses, usually painless, and may have rapid growth. The majority are clinically benign [2]. They are usually unilateral with <1% of cases occurring bilaterally [3, 4]. The etiology of phyllodes tumors remains unknown. Although, some suggest hyperestrinism or breast trauma may be a predisposing factors [5, 6]. Though imaging may aid in the diagnosis in some cases, mammography is often nondiagnostic. Reports using ultrasonography characterize a phyllodes as a solid lobulated nodule of well-defined contours with heterogeneous echotexture, which may be associated with cystic components [7]. As in our case, larger tumors often are characterized by imaging that includes CT scans and evaluation for metastasis. Biopsy remains the mainstay in establishing the diagnosis.

The World Health Organization (WHO) classification of phyllodes tumors includes three broad categories (benign, borderline and malignant). This classification does not include the size of the tumor. The WHO classification was made according to the mitotic activity observed, degree of cellular atypia, characteristics of tumor margins and the presence of stromal growth. The benign variants in general do not metastasize. However, they may grow aggressively and can recur locally. The malignant variants of phyllodes can metastasize hematogenously most commonly to the lungs, but it can metastasize to the bone, heart and liver as well. There is a continuing debate over the prognostic significance of tumor size. Thus, appropriate cut-off values for tumor size and associated prognosis have not been well defined.

The treatment for phyllodes tumors is wide local excision with sufficient margin of normal breast tissues irrespective of the histological features (at least 1 cm negative margin) [8]. Some tailoring of this approach is applied to clearly malignant tumors to obtain negative margins. Axillary lymph nodes are excised only if clinically enlarged or palpable, as phyllodes tumors do not typically metastasize via the lymphatics. Some authorities recommend mastectomy for borderline or malignant phyllodes tumors, especially if free margin cannot be achieved, or in cases of local tumor recurrence. There is currently no
evidence of proven benefit of adjuvant therapies, but they can be considered for high-risk phyllodes tumor, including those >5 cm, or with stromal overgrowth, or >10 mitoses per high-power field, or for those tumors with positive margins [9]. However, some have suggested that the risk of local recurrence or metastasis is <25% of tumors with a ‘malignant’ histologic grade [10]. Because there is a risk of local recurrence and for some tumors a risk of metastatic disease, long-term follow-up is mandatory. In the future, molecular analysis of tumor tissue may play a role in defining the treatment for phyllodes.

CONFLICT OF INTEREST STATEMENT

None declared.

REFERENCES

1. Roa JC, Tapia O, Carrasco P, Contreras E, Araya JC, Muñoz S, et al. Prognostic factors of phyllodes tumor of the breast. Pathol Int 2006;56:309–14.
2. Khan SA, Badve S. Phyllodes tumors of the breast. Curr Treat Options Oncol 2001;2:139–47.
3. Keelan PA, Myers JL, Wold LE, Katzmann JA, Gibney DJ. Phyllodes tumor: clinicopathologic review of 60 patients and flow cytometric analysis in 30 patients. Hum Pathol 1992;23:1048–54.
4. Stebbing JF, Nash AG. Diagnosis and management of phyllodes tumor of the breast: experience of 33 cases at a specialist center. Ann R Coll Surg Engl 1995;77:181–4.
5. Nielsen VT, Andreasen C. Phyllodes tumor of the male breast. Histopathology 1987;11:761–5.
6. Pantoja E, Llobet RE, Lopez E. Gigantic cystosarcoma phyllodes in a man with gynecomastia. Arch Surg 1976;111:611.
7. Tan PH, Jayabaskar T, Chuah KL, Lee HY, Tan Y, Hilmy M, et al. Phyllodes tumors of the breast: the role of pathologic parameters. Am J Clin Pathol 2005;123:529–40.
8. Noguchi S, Aihara T, Motomura K, Inaji H, Imaoka S, Koyama H, et al. Phyllodes tumor of the breast: pathology, histogenesis, diagnosis and treatment. Breast Cancer 1996;3:79–92.
9. Asoglu O, Ugurlu MM, Blanchard K, Grant CS, Reynolds C, Cha SS, et al. Risk factors for recurrence and death after primary surgical treatment of malignant phyllodes tumors. Ann Surg Oncol 2004;11:1011–7.
10. Guillot E, Couturaud B, Reyal F, Curnier A, Ravinet J, Laé M, et al. Management of phyllodes breast tumors. Breast J 2011;17:129–37.